Real-world postprogression outcomes after first-line treatment with ribociclib plus aromatase inhibitor versus aromatase inhibitor alone in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer in the United States of America. - Hart L; Rugo HS; Sharma P; Sammons S; Gadi VK; Mavros P; Kaur M; Boualam N; Keane C; Sopher G; Pathak P; Tarantino P (ESMO open, 2026)